Laurus Labs Ltd (LAURUSLABS)

Laurus Labs and Other CDMOs Expanding Capacities - 16 Jul, 2024

Divis Laboratories, Laurus Labs, Piramal Pharma, Suven Pharma, and JB Chemicals & Pharmaceuticals are expanding their CDMO businesses. New contracts can help Laurus Labs utilise capacities better.

Laurus Labs Breaks Above Resistance Level - 06 Jul, 2024

Laurus Labs Ltd's stock has broken above its swing high resistance level of 471, with strong trading volumes and a high RSI on daily charts indicating potential for further upward movement.

Laurus Labs Stock Breaks Out Amid CEO Compensation Concerns - 05 Jul, 2024

Laurus Labs' stock has broken out of its down-sloping trend line resistance, indicating an expected upside of 500-535. However, concerns have been raised about CEO Satyanarayana Chava's high compensation despite shareholder losses.

Laurus Labs Stock Price Likely to Rally - 04 Jul, 2024

The stock of Laurus Labs is expected to rally from the support level at ₹425, with a high probability of hitting ₹475 in the near term. Participants can consider buying the stock now at ₹437 and accumulate if it dips to ₹428, with a stop-loss at ₹418.

Laurus Labs Sees High Volume and P/S Ratio - 03 Jul, 2024

Laurus Labs saw high trading volume with 2.17 lakh shares traded on BSE, while its P/S ratio stands at 4.7x, higher than the industry average of 2.8x. The company's revenue growth has been inconsistent recently but analysts expect it to grow by 14% annually for the next three years.

CARE Ratings Revises Outlook on Laurus Labs' Long-Term Credit Facilities to Negative - 18 Jun, 2024

CARE Ratings has revised its outlook on the long-term credit facilities of Laurus Labs to negative from stable, while affirming the rating at CARE AA. The company's Q4 FY24 net profit dropped 26.58% YoY to Rs 75.61 crore, while revenue from operations increased 4.26% YoY to Rs 1,439.67 crore.